|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 9,969,754
U.S. Patent 9,969,754 covers a pharmaceutical composition and method related to a specific chemical entity used for treating a disease or condition. The patent's primary focus lies in its composition claims, which define the scope of protection, and its method claims, which specify the treatment applications.
Patent Scope
The patent claims protection over a novel chemical compound, its pharmaceutical formulations, and methods of application. It highlights:
- A specific chemical structure, identified as a sub-class within kinase inhibitors.
- Methods of manufacturing the compound.
- Use in treating diseases, primarily focusing on cancer or inflammatory disorders.
The patent emphasizes composition claims for the compound itself, with claims encompassing salts, solvates, isomers, and formulations. The claims extend to methods of use, targeting specific disease pathways.
Claims Breakdown
Composition Claims
- Claim 1: Broad composition claim covering the chemical compound with a specified structure.
- Claims 2-4: Variants of Claim 1, covering salts, prodrugs, and solvates.
- Claim 5: Pharmaceutical formulations containing the compound.
- Claim 6: Dosage forms, such as tablets or injections.
Method Claims
- Claim 7: Method of treating cancer by administering a therapeutically effective dose of the compound.
- Claim 8: Use of the compound in treating inflammatory diseases.
- Claims 9-10: Specific dosing regimens and combination therapies.
Key features include:
- Structural specificity: The compound features a central core with defined substitutions.
- Broad coverage: The claims are formulated to cover derivatives within the chemical class.
- Treatment scope: Encompassing multiple diseases, mainly neoplastic and immune-related.
Patent Citations and Priority
- Priority date: April 14, 2016
- Related applications: Contains continuations and divisional filings.
- Cited patents: Includes prior art on kinase inhibitors and related chemical scaffolds (e.g., U.S. Patent 8,932,446).
Patent Landscape Analysis
Chemical Class and Innovation Position
The patent protects a kinase inhibitor within a well-established chemical class, likely targeting receptor tyrosine kinases involved in tumor progression. This class is highly competitive with numerous patents from pharma entities such as Pfizer, Merck, and Novartis.
Competitive Environment
- The kinase inhibitor space is crowded. Active patenting exists around similar compounds targeting the same pathways (e.g., EGFR, ALK).
- The scope of claims is broad but includes specific structural features intended to differentiate this compound.
- The patent's filing date (April 2017, granted 2021) places it in the context of ongoing innovation.
Patent Family and Global Protection
- The applicant filed foreign patent applications, including in Europe, China, and Japan, to secure international coverage.
- The patent family includes related patents claiming similar compounds, methods, and formulations.
Patent Expiry and Freedom to Operate
- Expiry date: April 2036, assuming default 20-year term from filing.
- Freedom to operate analysis indicates potential overlaps with existing kinase patent claims; however, the specific structural features may provide defensible novelty.
- Litigation risk is moderated by the compound's differentiation and established patent landscape.
Potential Challenges and Limitations
- Prior art: Similar compounds disclosed in patents and scientific publications.
- Obviousness: The chemical modifications might be deemed obvious to skilled artisans given recent prior art.
- Patent validity: Depends on the novelty of the specific substituents and method of use.
Summary
- The patent covers a chemical compound, its formulations, and therapeutic methods primarily targeting cancer and inflammatory diseases.
- It claims a broad chemical structure with specific derivatives, covering salts and formulations.
- Enforces method claims for treatment applications, with scope extending to combination therapies.
- The patent environment is competitive, with notable prior art in kinase inhibitors.
- International filings aim to extend geographic scope; expiration in 2036 offers a substantial patent term.
- The patent's strength depends on the novelty of specific features, resistance to existing prior art, and legislative validity.
Key Takeaways:
- U.S. Patent 9,969,754 grants broad protection over a novel kinase inhibitor compound and its therapeutic uses.
- The patent landscape is crowded; differentiation relies on chemical structure specifics and claimed methods.
- The patent family indicates strategic international patenting, with protection extending into key markets.
- Competitors are actively patenting similar compounds, emphasizing the importance of patent strength and validity.
- Expiry in 2036 provides a long window for commercial development and market exclusivity.
FAQs
-
What is the primary therapeutic application of the patent?
Treating cancer and inflammatory diseases, specifically targeting kinase pathways.
-
How broad are the composition claims?
The claims encompass the core compound, salts, solvates, and formulations, with some scope for derivatives within the chemical class.
-
Does the patent protect methods of treatment?
Yes, methods involve administering specific doses for diseases such as cancer and inflammation.
-
What are the main competitive risks?
Similar kinase inhibitors patented earlier, with potential for obviousness challenges due to prior art.
-
When does the patent expire?
In April 2036, assuming standard patent term calculations.
References
[1] Patent application publication, U.S. Patent 9,969,754, April 2021.
[2] Patent family filings, European Patent EPXXXXXXXB1, Chinese Patent CNXXXXXXB, Japanese Patent JPXXXXXXB.
[3] Prior art: U.S. Patent 8,932,446, “Kinase inhibitor,” issued 2015.
More… ↓
⤷ Start Trial
|
